Spred-3 mutation and Ras/Raf/MAPK activation confer acquired resistance to EGFR tyrosine kinase inhibitor in an EGFR mutated NSCLC cell line

Translational Cancer Research ◽

10.21037/tcr.2020.03.05 ◽

2020 ◽

Vol 9 (4) ◽

pp. 2542-2555

Author(s):

Zhiyong He ◽

Fusheng Gong ◽

Jinrong Liao ◽

Qiang Wang ◽

Ying Su ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Cell Line ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Nsclc Cell Line ◽

Egfr Tyrosine Kinase Inhibitor ◽

Mapk Activation ◽

Download Full-text

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Case Medical Research ◽

10.31525/ct1-nct04007835 ◽

2019 ◽

Author(s):

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Advanced Nsclc ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Nsclc Patients ◽

Download Full-text

Phase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor

Annals of Oncology ◽

10.1093/annonc/mdx380.080 ◽

2017 ◽

Vol 28 ◽

pp. v493 ◽

Author(s):

K. Park ◽

F. Ciardiello ◽

T. Hida ◽

W. Lim ◽

C-C. Lin ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Nsclc Patients ◽

Download Full-text

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

Cell Reports ◽

10.1016/j.celrep.2019.05.058 ◽

2019 ◽

Vol 27 (12) ◽

pp. 3422-3432.e4 ◽

Author(s):

Lynnette Marcar ◽

Kankana Bardhan ◽

Liliana Gheorghiu ◽

Patrick Dinkelborg ◽

Heike Pfäffle ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Parp Inhibitor ◽

Acquired Resistance ◽

Egfr Mutated ◽

Inhibitor Treatment

Download Full-text

Spatiotemporal T790M heterogeneity in individual patients with non-small cell lung cancer (NSCLC) after acquired resistance to EGFR-tyrosine kinase inhibitor (TKI).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8067 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8067-8067 ◽

Author(s):

Akito Hata ◽

Nobuyuki Katakami ◽

Hiroshige Yoshioka ◽

Katsuhiro Masago ◽

Shiro Fujita ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling

Breast Cancer Research and Treatment ◽

10.1007/s10549-007-9830-2 ◽

2007 ◽

Vol 112 (1) ◽

pp. 25-33 ◽

Author(s):

Nicola Normanno ◽

Manuela Campiglio ◽

Monica R. Maiello ◽

Antonella De Luca ◽

Mario Mancino ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Cancer Cells ◽

Breast Cancer Cells ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Mapk Signaling ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients

10.18632/oncotarget.7189 ◽

2016 ◽

Vol 7 (11) ◽

pp. 12404-12413 ◽

Author(s):

Shang-Gin Wu ◽

Yi-Nan Liu ◽

Meng-Feng Tsai ◽

Yih-Leong Chang ◽

Chong-Jen Yu ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Abstract LB-123: Analysis of cell-free plasma DNA (cfDNA) identifies 3 molecular subtypes of acquired resistance to AZD9291, a novel EGFR tyrosine kinase inhibitor (TKI), in patients (pts) with advanced lung cancer

10.1158/1538-7445.am2015-lb-123 ◽

2015 ◽

Author(s):

Geoffrey R. Oxnard ◽

Kenneth S. Thress ◽

Cloud P. Paweletz ◽

Enriqueta Felip ◽

Byoung Chul Cho ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Molecular Subtypes ◽

Acquired Resistance ◽

Advanced Lung Cancer ◽

Egfr Tyrosine Kinase Inhibitor ◽

Download Full-text

Acquired resistance to EGFR tyrosine kinase inhibitor in A431 squamous cell carcinoma xenografts is mediated by c-Kit pathway transduction

Tumor Biology ◽

10.1007/s13277-014-2932-7 ◽

2014 ◽

Vol 36 (4) ◽

pp. 2993-2999 ◽

Author(s):

Lixia Zhang ◽

Xiaokun Yang ◽

Bei Zhao ◽

Zhen Cai

Keyword(s):

Squamous Cell Carcinoma ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Cell Carcinoma ◽

Squamous Cell ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR -mutated lung cancer: a single institution's clinical practice experience

Cancer Communications ◽

10.1186/s40880-018-0321-0 ◽

2018 ◽

Vol 38 (1) ◽

pp. 51 ◽

Author(s):

Xiangyang Yu ◽

Xuewen Zhang ◽

Zichen Zhang ◽

Yongbin Lin ◽

Yingsheng Wen ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Practice ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

First Generation ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Practice Experience ◽

Tyrosine Kinase Inhibitor Therapy ◽

Download Full-text

New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer

Annals of Oncology ◽

10.1093/annonc/mdz063.030 ◽

2019 ◽

Vol 30 ◽

pp. ii51

Author(s):

J. Fassunke ◽

C. Heydt ◽

S. Michels ◽

B. Van Veggel ◽

F. Müller ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Resistance Mechanisms ◽

Third Generation ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text